The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

By Nancy Lapid (Reuters) -Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to ...

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami ...

Palliative nurse's notes, Aug. 2, 2019: "Participated in Hospice meeting with patient. Seth (spouse), mother, father, bedside RN. Andrea from Hospice was on speakerphone. Discussed philosophy of ...

Summit Therapeutics said its closely tracked antibody, the first lung cancer drug to beat Merck’s Keytruda in a head-to-head ...

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...